Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Dr Reddys Laboratories ADR repsg 1 Ord Shs RDY

Healthcare
Dr. Reddy’s Laboratories Limited is an India-based global pharmaceutical company. The Company offers a portfolio of products and services, including active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC). Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. The... see more

Recent & Breaking News (NYSE:RDY)

Dr. Reddy's Laboratories Announces the Launch of Fosaprepitant for Injection in the U.S. Market

Business Wire September 11, 2019

Dr. Reddy's Laboratories Limited to Present at the Morgan Stanley Annual Global Healthcare Conference

Business Wire September 6, 2019

Dr. Reddy's Laboratories announces the launch of Bupropion Hydrochloride Extended-Release Tablets, USP (SR) in the U.S. Market

Business Wire September 5, 2019

Dr. Reddy's Laboratories Announces the Launch of Vigabatrin Powder for Oral Solution, USP in the U.S. Market

Business Wire August 20, 2019

Dr. Reddy's Laboratories announces the launch of Versavo® (bevacizumab biosimilar) in India

Business Wire August 19, 2019

Exelixis and Aurigene Enter Into Exclusive Collaboration, Option and License Agreement to Discover and Develop Novel Therapies for Cancer

Business Wire July 31, 2019

Dr. Reddy's Laboratories announces the launch of Pregabalin Capsules in the U.S. Market

Business Wire July 30, 2019

Dr. Reddy's Q1 FY20 Financial Results

Business Wire July 29, 2019

Dr. Reddy's Laboratories Announces the Launch of Ramelteon Tablets, in the U.S. Market

Business Wire July 23, 2019

Upsher-Smith Laboratories Completes Acquisition Of Two Treatments For Acute Migraine In Adults

PR Newswire July 20, 2019

Dr. Reddy's Laboratories announces closure of the transaction to divest ZEMBRACE® SYMTOUCH® and TOSYMRA(TM) to Upsher-Smith Laboratories, LLC

Business Wire July 20, 2019

Dr. Reddy's announces the launch of over-the-counter, store-brand equivalent of Allegra-D® 12 HR Allergy and Congestion Extended-Release Tablets (fexofenadine HCl 60 mg and pseudoephedrine HCl 120 mg) in the U.S. Market

Business Wire July 19, 2019

Dr. Reddy's to release Q1 FY 20 results on July 29, 2019

Business Wire July 10, 2019

Dr. Reddy's Announces the Launch of the Over-the-counter Store Brand Equivalent of Mucinex® D Extended Release Tablets in Two Strengths in the U.S. Market

Business Wire July 9, 2019

Dr. Reddy's Laboratories Announces First-to-market Launch of Carboprost Tromethamine Injection USP, 250 mcg/mL (1mL) Single-dose Vial in the U.S. Market

Business Wire July 3, 2019

Dr. Reddy's Laboratories Announces the Launch of Tobramycin Inhalation Solution, USP in the U.S. Market

Business Wire June 25, 2019

Dr. Reddy's Laboratories Announces the Launch of Phytonadione Injectable Emulsion USP, 10 mg/ml Single-Dose Ampules in the U.S. Market

Business Wire June 22, 2019

Dr. Reddy's Laboratories Announces Entering into a Definitive Agreement to Sell Its Neurology Branded Products to Upsher-Smith Laboratories, LLC

Business Wire June 14, 2019

Upsher-Smith Laboratories Enters Into Agreement To Acquire Tosymra(TM) (sumatriptan nasal spray) And Zembrace® SymTouch® (sumatriptan injection)

PR Newswire June 13, 2019

Dr. Reddy's Laboratories Limited Through Its Wholly Owned Subsidiary, Dr. Reddy's Laboratories SA, Announces Positive Topline Results from Phase 2b Study of PPC-06 in Patients with Moderate to Severe Plaque Psoriasis

Business Wire June 10, 2019